Results 101 to 110 of about 3,395 (155)

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)

Microorganisms
Background. Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global mortality, often associated with high blood levels of LDL cholesterol (LDL-c).
Jose A. Caparrós-Martín, Patrice Maher, Natalie C. Ward, Montserrat Saladié, Patricia Agudelo-Romero, Stephen M. Stick, Dick C. Chan, Gerald F. Watts, Fergal O’Gara   +8 more
doaj   +1 more source

A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

Communications Medicine
Background Dyslipidemia is a known risk factor for cardiovascular disease. While statins are the primary treatment, some individuals require additional lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Michael Asger Andersen, Anne Helms Andreasen, Lia Evi Bang, Espen Jimenez-Solem, Tonny Studsgaard Petersen   +4 more
doaj   +1 more source

Evaluating bempedoic acid for the treatment of hyperlipidaemia [PDF]

Introduction: Despite the effectiveness of statins in the treatment of lipid disorders, residual risk still exists, and hitherto studies where additional drugs were added to statin therapy have been mainly negative or the outcomes were very modest ...
Banach, M, McGowan, M, Penson, P
core   +1 more source

PCSK9 as a Biomarker for Cardiovascular Risk [PDF]

Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) is a protein that prevents low-density lipoprotein (LDL) clearance from plasma through degradation of low-density lipoprotein receptors (LDL-R).
McKinnon, Tyler J
core   +1 more source

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease [PDF]

, 2018
Banach, Maciej, Cannon, Christopher P, Colhoun, Helen M, Dwyer, Jamie P, Koren, Andrew, Letierce, Alexia, Louie, Michael J, Mandel, Jonas, Rader, Daniel J, Toth, Peter P, Upadhyay, Ashish   +10 more
core   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to
Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu   +4 more
doaj   +1 more source

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]

, 2015
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M, Gadi, Ramprasad   +1 more
core   +1 more source

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells

BMC Cardiovascular Disorders
Background Atherosclerosis is a complex inflammatory disease driven by endothelial dysfunction. However, most in vitro studies rely on lipopolysaccharide (LPS) or oxidized LDL (oxLDL) as stimulants, overlooking the pathogenic role of lipoprotein(a) [Lp(a)
Rahayu Zulkapli, Suhaila Abd Muid, Seok Mui Wang, Mohd Yusmiaidil Putera Mohd Yusof, Hapizah Nawawi   +4 more
doaj   +1 more source

Alirocumab’s Price Reduction [PDF]

Circulation, 2018
Sanket S. Dhruva, Joseph S. Ross, Nihar R. Desai   +2 more
openaire   +1 more source

PCSK9 Inhibitors for LDL Lowering [PDF]

, 2015
Walsh, James P.
core   +1 more source